Create a formative OSCE station describing how to demonstrate and educate a 68‑year‑old male with amyotrophic lateral sclerosis on the use of a cough assist device to augment cough and clear secretions.

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 7, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

FICM OSCE Station: Cough Assist Device Education in ALS

Station Overview

Time: 10 minutes
Candidate Role: ICU physician/physiotherapist
Patient: 68-year-old male with ALS and impaired cough effectiveness
Task: Demonstrate and educate on mechanical insufflation-exsufflation (MI-E) device use


Candidate Instructions

You are seeing Mr. Thompson, a 68-year-old man with amyotrophic lateral sclerosis diagnosed 18 months ago. He has progressive limb weakness and is now experiencing difficulty clearing secretions. His peak cough expiratory flow is 180 L/min, and maximal expiratory pressure is 42 cm H₂O. He has mild bulbar symptoms (Norris bulbar score 32/39). He lives at home with his wife who will be his primary caregiver.

Your tasks:

  1. Assess his understanding of why he needs this device
  2. Demonstrate proper use of the MI-E device
  3. Educate him and his caregiver on technique, settings, and troubleshooting
  4. Address safety concerns and when to seek help

Examiner Instructions

Setting: Simulated home care environment with MI-E device (cough assist), face mask, and mouthpiece interfaces available.

Standardized Patient Brief:

  • You are concerned about choking on secretions
  • You've heard the device is uncomfortable
  • You want to know how often to use it
  • Your wife is anxious about using medical equipment

Assessment Domains:

  1. Clinical Assessment (25%)

    • Identifies indications: PCF <270 L/min, MEP <60 cm H₂O 1
    • Recognizes bulbar involvement implications 2, 3
    • Assesses baseline oxygen saturation
  2. Technical Demonstration (35%)

    • Device setup and interface selection:

      • Explains mask vs. mouthpiece options
      • Checks device connections and power
    • Parameter setting based on patient factors:

      • Initial settings: Start ±20 cm H₂O due to bulbar symptoms 2, 3
      • Explains rationale: bulbar dysfunction causes laryngeal adduction during insufflation 4, 2
      • Plans gradual titration to ±30-40 cm H₂O if tolerated
      • Avoids starting at ±50 cm H₂O which can worsen upper airway obstruction 3
    • Proper technique sequence:

      • Position patient semi-recumbent (30-45 degrees)
      • Apply interface ensuring good seal
      • Coordinate with patient's breathing
      • Insufflation phase: 1-2 seconds, watch for chest rise
      • Brief pause (0.5-1 second) for glottic closure
      • Exsufflation phase: 2-3 seconds, observe secretion mobilization
      • 5-6 cycles per treatment session 1, 5
  3. Patient Education (25%)

    • Frequency and timing:

      • Minimum twice daily for maintenance 1
      • Increase to 4-6 times daily during respiratory infections 1
      • Use before meals to clear secretions
    • Recognizing effectiveness:

      • Audible secretion movement
      • Improved oxygen saturation (maintain SpO₂ ≥95%) 6
      • Reduced work of breathing
    • Troubleshooting bulbar-related issues:

      • If ineffective at current settings, check for laryngeal obstruction patterns 4
      • May need to reduce insufflation pressure if paradoxically worsening 2, 3
      • Consider adding manual abdominal thrust during exsufflation 1
      • Coordinate with air stacking techniques for volume recruitment 7
  4. Safety and Complications (15%)

    • Expected side effects:

      • Transient nausea, abdominal distention 1
      • Mild bradycardia or tachycardia 1
    • Warning signs requiring medical attention:

      • SpO₂ drops below 90% despite treatment 6
      • Persistent respiratory distress
      • Hemoptysis
      • Severe chest pain
    • Contraindications to mention:

      • Active pneumothorax
      • Recent barotrauma
      • Severe cardiovascular instability

Key Evidence-Based Points

Indications for MI-E in ALS:

  • Peak cough flow <270 L/min indicates need for assisted cough techniques 1
  • MEP <60 cm H₂O correlates with ineffective cough 1
  • MI-E superior to manual techniques and breath stacking for generating peak flows 1

Critical ALS-Specific Considerations:

  • Bulbar dysfunction causes laryngeal adduction during insufflation, especially at high pressures 4, 2, 3
  • Upper motor neuron bulbar signs predict obstruction during insufflation 4
  • Lower motor neuron bulbar signs predict airway collapse during exsufflation 4
  • Individually customized pressure settings prevent laryngeal obstruction 2
  • Adverse laryngeal responses can occur before clinical bulbar symptoms in spinal-onset ALS 3

Outcomes:

  • Prevents hospitalization and reduces need for tracheostomy when PCF around 160 L/min 1
  • On-demand access programs with MI-E avoid 30+ hospitalizations per cohort 6
  • 98.55% of ALS patients achieve effective MI-E after parameter adjustment 4

Marking Scheme

Pass Standard: Candidate must demonstrate safe device use with appropriate pressure settings for bulbar involvement, explain frequency of use, and identify key warning signs.

Critical Failures (Automatic Fail):

  • Starting with high pressures (≥40 cm H₂O) without assessing bulbar function
  • Failing to recognize need for lower pressures with bulbar symptoms
  • Not explaining when to seek emergency help
  • Unsafe technique risking barotrauma

Model Answer Key Points

"Mr. Thompson needs this device because his cough muscles are too weak to clear secretions effectively—your peak cough flow of 180 L/min is below the 270 L/min threshold where secretion clearance becomes problematic." 1

"Because you have some bulbar symptoms, we'll start with gentler pressures of ±20 cm H₂O rather than the higher settings, as your larynx may close reflexively during the insufflation phase, making the treatment less effective or uncomfortable." 4, 2, 3

"Use this at least twice daily, and increase to 4-6 times when you have a cold or respiratory infection. Your wife should monitor your oxygen levels—if they drop below 95% and don't improve with treatment, call us immediately." 1, 6

"The device prevents pneumonia and hospitalization by clearing secretions from deep in your lungs, which regular coughing or suctioning cannot reach." 1

Related Questions

Based on my CT pulmonary angiogram results, should I be concerned about amyotrophic lateral sclerosis (ALS)?
Do easy inspiration with marked difficulty expelling air (expiratory flow limitation and air‑trapping) coincide with amyotrophic lateral sclerosis (ALS)?
Can respiratory symptoms occur in amyotrophic lateral sclerosis (ALS) without any limb, trunk, or facial muscle weakness, presenting only with dyspnea and fasciculations?
What are the indications for initiating a cough‑assist (mechanical insufflation‑exsufflation) device in a 68‑year‑old man with amyotrophic lateral sclerosis who has a peak cough flow of 180 L/min, maximal expiratory pressure of 42 cm H₂O, mild bulbar involvement, and difficulty clearing secretions?
In a female patient presenting with progressive dyspnea on exertion and at night, widespread fasciculations, and no limb, trunk, or facial weakness, is amyotrophic lateral sclerosis (ALS) likely?
What is the proper method to dilute glyceryl trinitrate (nitroglycerin) for intravenous infusion?
When should a psychiatrist be consulted for patients in critical care who exhibit agitation, delirium, psychosis, suicidal ideation, or other acute mental‑status changes?
What does a strawberry tongue indicate and how should it be evaluated and managed?
How should a patient presenting with a strawberry‑appearing tongue be evaluated and managed?
What are the typical clinical presentation, symptoms, and physical examination findings in a young to middle‑aged adult, usually female, with rheumatic mitral stenosis?
What are the side effects of infliximab (Remicade)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.